JOHN KIRKWOOD to Sulfonamides
This is a "connection" page, showing publications JOHN KIRKWOOD has written about Sulfonamides.
Connection Strength
0.452
-
A phase 2 study of tasisulam sodium (LY573636 sodium) as second-line treatment for patients with unresectable or metastatic melanoma. Cancer. 2011 Oct 15; 117(20):4732-9.
Score: 0.192
-
The HDAC inhibitor AR42 interacts with pazopanib to kill trametinib/dabrafenib-resistant melanoma cells in vitro and in vivo. Oncotarget. 2017 Mar 07; 8(10):16367-16386.
Score: 0.073
-
Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol. 2014 Mar; 15(3):323-32.
Score: 0.059
-
New challenges in endpoints for drug development in advanced melanoma. Clin Cancer Res. 2012 Jan 15; 18(2):336-41.
Score: 0.050
-
Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011 Jun 30; 364(26):2507-16.
Score: 0.049
-
Pan-erbB inhibition potentiates BRAF inhibitors for melanoma treatment. Melanoma Res. 2014 Jun; 24(3):207-18.
Score: 0.015
-
PDGFRa up-regulation mediated by sonic hedgehog pathway activation leads to BRAF inhibitor resistance in melanoma cells with BRAF mutation. Oncotarget. 2014 Apr 15; 5(7):1926-41.
Score: 0.015